Browse PLAU

Summary
SymbolPLAU
Nameplasminogen activator, urokinase
Aliases URK; BDPLT5; QPD; u-PA; U-plasminogen activator; plasminogen activator, urinary; Urokinase-type plasminogen ......
Chromosomal Location10q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00051 Kringle domain
PF00089 Trypsin
Function

Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.

> Gene Ontology
 
Biological Process GO:0001666 response to hypoxia
GO:0001952 regulation of cell-matrix adhesion
GO:0007160 cell-matrix adhesion
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0010469 regulation of receptor activity
GO:0010810 regulation of cell-substrate adhesion
GO:0014812 muscle cell migration
GO:0014909 smooth muscle cell migration
GO:0014910 regulation of smooth muscle cell migration
GO:0030193 regulation of blood coagulation
GO:0030195 negative regulation of blood coagulation
GO:0030335 positive regulation of cell migration
GO:0031589 cell-substrate adhesion
GO:0032102 negative regulation of response to external stimulus
GO:0033627 cell adhesion mediated by integrin
GO:0033628 regulation of cell adhesion mediated by integrin
GO:0036293 response to decreased oxygen levels
GO:0040017 positive regulation of locomotion
GO:0042730 fibrinolysis
GO:0050817 coagulation
GO:0050818 regulation of coagulation
GO:0050819 negative regulation of coagulation
GO:0050878 regulation of body fluid levels
GO:0051272 positive regulation of cellular component movement
GO:0061041 regulation of wound healing
GO:0061045 negative regulation of wound healing
GO:0061302 smooth muscle cell-matrix adhesion
GO:0070482 response to oxygen levels
GO:1900046 regulation of hemostasis
GO:1900047 negative regulation of hemostasis
GO:1903034 regulation of response to wounding
GO:1903035 negative regulation of response to wounding
GO:2000097 regulation of smooth muscle cell-matrix adhesion
GO:2000147 positive regulation of cell motility
Molecular Function GO:0004175 endopeptidase activity
GO:0004252 serine-type endopeptidase activity
GO:0008236 serine-type peptidase activity
GO:0017171 serine hydrolase activity
Cellular Component GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0030055 cell-substrate junction
> KEGG and Reactome Pathway
 
KEGG hsa04064 NF-kappa B signaling pathway
hsa04610 Complement and coagulation cascades
Reactome R-HSA-75205: Dissolution of Fibrin Clot
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6798695: Neutrophil degranulation
Summary
SymbolPLAU
Nameplasminogen activator, urokinase
Aliases URK; BDPLT5; QPD; u-PA; U-plasminogen activator; plasminogen activator, urinary; Urokinase-type plasminogen ......
Chromosomal Location10q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PLAU and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PLAU and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
19196663LymphomaInhibit immunityBecause MUC1/sec was previously shown to down-regulate tumor expression of urokinase plasminogen activator (uPA), a protease linked to tumor aggressiveness and metastasis, the potential role of uPA in MDSC recruitment was investigated. Tumor-derived uPA is capable of recruiting MDSCs, and correlates with tumor development.
Summary
SymbolPLAU
Nameplasminogen activator, urokinase
Aliases URK; BDPLT5; QPD; u-PA; U-plasminogen activator; plasminogen activator, urinary; Urokinase-type plasminogen ......
Chromosomal Location10q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PLAU in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPLAU
Nameplasminogen activator, urokinase
Aliases URK; BDPLT5; QPD; u-PA; U-plasminogen activator; plasminogen activator, urinary; Urokinase-type plasminogen ......
Chromosomal Location10q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PLAU in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7670.182
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.0860.631
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5070.696
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.6120.291
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.1340.587
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0560.984
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0650.92
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1820.902
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0360.983
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6250.681
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.8050.405
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4110.027
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PLAU in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPLAU
Nameplasminogen activator, urokinase
Aliases URK; BDPLT5; QPD; u-PA; U-plasminogen activator; plasminogen activator, urinary; Urokinase-type plasminogen ......
Chromosomal Location10q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PLAU. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPLAU
Nameplasminogen activator, urokinase
Aliases URK; BDPLT5; QPD; u-PA; U-plasminogen activator; plasminogen activator, urinary; Urokinase-type plasminogen ......
Chromosomal Location10q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PLAU. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PLAU.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPLAU
Nameplasminogen activator, urokinase
Aliases URK; BDPLT5; QPD; u-PA; U-plasminogen activator; plasminogen activator, urinary; Urokinase-type plasminogen ......
Chromosomal Location10q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PLAU. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPLAU
Nameplasminogen activator, urokinase
Aliases URK; BDPLT5; QPD; u-PA; U-plasminogen activator; plasminogen activator, urinary; Urokinase-type plasminogen ......
Chromosomal Location10q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PLAU expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPLAU
Nameplasminogen activator, urokinase
Aliases URK; BDPLT5; QPD; u-PA; U-plasminogen activator; plasminogen activator, urinary; Urokinase-type plasminogen ......
Chromosomal Location10q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PLAU and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPLAU
Nameplasminogen activator, urokinase
Aliases URK; BDPLT5; QPD; u-PA; U-plasminogen activator; plasminogen activator, urinary; Urokinase-type plasminogen ......
Chromosomal Location10q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PLAU collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PLAU.
ID Name Drug Type Targets #Targets
DB00013UrokinaseBiotechLRP2, NID1, PLAT, PLAU, PLAUR, PLG, SERPINA5, SERPINB2, SERPINE1, ......10
DB00594AmilorideSmall MoleculeAOC1, ASIC1, ASIC2, PLAU, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC9A19
DB017252-{2-hydroxy-[1,1'-biphenyl]-3-yl}-1H-1,3-benzodiazole-5-carboximidamideSmall MoleculeF2, PLAU, PRSS13
DB019052-(2-Hydroxy-5-Methoxy-Phenyl)-1h-Benzoimidazole-5-CarboxamidineSmall MoleculePLAU, PRSS12
DB019776-(N-Phenylcarbamyl)-2-NaphthalenecarboxamidineSmall MoleculePLAU1
DB022872-(2-Hydroxy-Phenyl)-3h-Benzoimidazole-5-CarboxamidineSmall MoleculeF2, PLAU, PRSS13
DB023986-[N-(4-(Aminomethyl)Phenyl)Carbamyl]-2-NaphthalenecarboxamidineSmall MoleculePLAU1
DB024736-[N-(1-Isopropyl-3,4-Dihydro-7-Isoquinolinyl)Carbamyl]-2-NaphthalenecarboxamidineSmall MoleculePLAU1
DB02526CRA_10655Small MoleculePLAU, PRSS12
DB025516-[N-(4-Ethyl-1,2,3,4-Tetrahydro-6-Isoquinolinyl)Carbamyl]-2-NaphthalenecarboxamidineSmall MoleculePLAU1
DB027056-[N-(1-Isopropyl-1,2,3,4-Tetrahydro-7-Isoquinolinyl)Carbamyl]-2-NaphthalenecarboxamidineSmall MoleculePLAU1
DB030467-Methoxy-8-[1-(Methylsulfonyl)-1h-Pyrazol-4-Yl]Naphthalene-2-CarboximidamideSmall MoleculePLAU1
DB030826-[(Z)-Amino(Imino)Methyl]-N-[4-(Aminomethyl)Phenyl]-4-(Pyrimidin-2-Ylamino)-2-NaphthamideSmall MoleculePLAU1
DB03127BenzamidineSmall MoleculeATOX1, CSNK2A1, ECI1, KLK1, KLK6, PLAU, PRSS1, PRSS2, PRSS3, ST1410
DB031364-Iodobenzo[B]Thiophene-2-CarboxamidineSmall MoleculeF2, PLAU, PRSS13
DB03159CRA_8696Small MoleculeF2, PLAU, PRSS13
DB03476Trans-6-(2-Phenylcyclopropyl)-Naphthalene-2-CarboxamidineSmall MoleculePLAU1
DB037292-Amino-5-Hydroxy-BenzimidazoleSmall MoleculePLAU1
DB03782N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)UreaSmall MoleculePLAU1
DB038656-Chloro-2-(2-Hydroxy-Biphenyl-3-Yl)-1h-Indole-5-CarboxamidineSmall MoleculeF2, HPN, PLAU, PRSS14
DB03876Thieno[2,3-B]Pyridine-2-CarboxamidineSmall MoleculePLAU, PRSS12
DB040598-(Pyrimidin-2-Ylamino)Naphthalene-2-CarboximidamideSmall MoleculePLAU1
DB04172[2,4,6-Triisopropyl-Phenylsulfonyl-L-[3-Amidino-Phenylalanine]]-Piperazine-N'-Beta-AlanineSmall MoleculePLAU1
DB05254FibrinolysinBiotechPLAU, SERPINE12
DB068556-fluoro-2-(2-hydroxy-3-isobutoxy-phenyl)-1H-benzoimidazole-5-carboxamidineSmall MoleculePLAU, PRSS12
DB068566-FLUORO-2-[2-HYDROXY-3-(2-METHYL-CYCLOHEXYLOXY)-PHENYL]-1H-INDOLE-5-CARBOXAMIDINESmall MoleculePLAU1
DB06857N-(4-CARBAMIMIDOYL-3-CHORO-PHENYL)-2-HYDROXY-3-IODO-5-METHYL-BENZAMIDESmall MoleculePLAU1
DB070766-[(Z)-AMINO(IMINO)METHYL]-N-[3-(CYCLOPENTYLOXY)PHENYL]-2-NAPHTHAMIDESmall MoleculePLAU1
DB071221-[4-(2-oxo-2-phenylethyl)phenyl]guanidineSmall MoleculePLAU1
DB07129(2R)-1-(2,6-dimethylphenoxy)propan-2-amineSmall MoleculePLAU1
DB076254-(2-aminoethoxy)-N-(2,5-diethoxyphenyl)-3,5-dimethylbenzamideSmall MoleculePLAU1
DB076264-(2-aminoethoxy)-N-(3-chloro-2-ethoxy-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamideSmall MoleculePLAU1
DB080724-(2-AMINOETHOXY)-3,5-DICHLORO-N-[3-(1-METHYLETHOXY)PHENYL]BENZAMIDESmall MoleculePLAU1
DB086974-(2-aminoethoxy)-N-(3-chloro-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamideSmall MoleculePLAU1